AAPC of ASMR and age-standardized DALYs for cardiovascular diseases attributable to secondhand smoke in countries with increasing trends. حسب Juan Dong (342384)

الموضوعات:

Cortisol and prolactin concentration in non-pregnant women. حسب Francois Kiemde (5369657)

الموضوعات:

PA triggers autophagy in osteosarcoma cells. حسب Zeyu Zhan (22305085)

الموضوعات:

ASMR and age-standardized DALYs for cardiovascular diseases attributable to secondhand smoke, 1990–2019. حسب Juan Dong (342384)

الموضوعات:

S1 Data - حسب Francois Kiemde (5369657)

الموضوعات:

Interplay or correlation of cortisol on prolactin during pregnancy. حسب Francois Kiemde (5369657)

الموضوعات:

Molecular Docking Analysis of PA with its core target. حسب Zeyu Zhan (22305085)

الموضوعات:

Dynamics of cortisol levels measured in pregnant women during pregnancy determined at different ANC visits. حسب Francois Kiemde (5369657)

الموضوعات:

Cortisol and prolactin concentration in peripheral blood and umbilical cord blood at delivery. حسب Francois Kiemde (5369657)

الموضوعات:

PA-induced apoptosis in osteosarcoma cells. حسب Zeyu Zhan (22305085)

الموضوعات:

PA inhibits the proliferation of osteosarcoma cells. حسب Zeyu Zhan (22305085)

الموضوعات:

Malaria infection by gestation and gestational age. حسب Francois Kiemde (5369657)

الموضوعات:

GO and KEGG analysis results of PA against osteosarcoma. حسب Zeyu Zhan (22305085)

الموضوعات:

Potential targets and PPI networks of PA against osteosarcoma. حسب Zeyu Zhan (22305085)

الموضوعات:

Interplay or correlation of prolactin on cortisol during pregnancy. حسب Francois Kiemde (5369657)

الموضوعات:

Characteristic of study population. حسب Francois Kiemde (5369657)

الموضوعات:

Potential mechanism of anti-osteosarcoma activity of PA. حسب Zeyu Zhan (22305085)

الموضوعات:

Dynamic of prolactin in pregnant women during pregnancy. حسب Francois Kiemde (5369657)

الموضوعات:

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF حسب Qiong Jie (13270095)

"…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …"